Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$3.93 -1.3%	$3.28	$1.07 ▼ $4.08	$1.03B	0.88	3.17 million shs	2.73 million shs
MLYS Mineralys Therapeutics	$14.49 -1.0%	$14.92	$8.24 ▼ $18.38	$954.17M	-0.3	555,138 shs	442,534 shs
SYRE Spyre Therapeutics	$15.69 -1.7%	$15.47	$10.91 ▼ $40.26	$962M	2.68	579,420 shs	491,411 shs
VOR Vor Biopharma	$2.50 +8.2%	$0.64	$0.13 ▼ $3.29	$312.40M	2.04	4.74 million shs	15.99 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-1.26%	+9.02%	+10.08%	+138.18%	+263.89%
MLYS Mineralys Therapeutics	-1.02%	-0.24%	-6.82%	+8.13%	+10.61%
SYRE Spyre Therapeutics	-1.69%	-0.95%	-12.83%	+28.40%	-43.72%
VOR Vor Biopharma	+8.23%	+32.63%	+1,036.36%	+257.14%	+164.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKBA Akebia Therapeutics	3.5829 of 5 stars	3.6	1.0	4.0	1.4	0.8	0.6
MLYS Mineralys Therapeutics	2.3579 of 5 stars	3.4	1.0	0.0	2.4	4.2	0.0
SYRE Spyre Therapeutics	1.9383 of 5 stars	3.6	0.0	0.0	1.6	2.5	0.6
VOR Vor Biopharma	3.9134 of 5 stars	4.3	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	3.20	Buy	$6.75	71.76% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	122.57% Upside
SYRE Spyre Therapeutics	3.25	Buy	$53.40	240.34% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	125.14% Upside

Current Analyst Ratings Breakdown

Latest VOR, AKBA, SYRE, and MLYS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
6/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$184.91M	5.58	N/A	N/A	($0.23) per share	-17.09
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
SYRE Spyre Therapeutics	$890K	1,062.69	N/A	N/A	$7.04 per share	2.23
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$69.41M	-$0.21	N/A	N/A	N/A	-24.51%	N/A	-18.92%	8/6/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)
SYRE Spyre Therapeutics	-$208.02M	-$3.77	N/A	N/A	N/A	N/A	-77.46%	-41.06%	8/6/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, AKBA, SYRE, and MLYS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	SYRE Spyre Therapeutics	-$0.68	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/8/2025	Q1 2025	SYRE Spyre Therapeutics	-$0.76	-$0.74	+$0.02	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	1.89	2.23	2.02
MLYS Mineralys Therapeutics	N/A	26.48	26.48
SYRE Spyre Therapeutics	N/A	8.06	8.06
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
MLYS Mineralys Therapeutics	84.46%
SYRE Spyre Therapeutics	80.39%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	3.00%
MLYS Mineralys Therapeutics	25.56%
SYRE Spyre Therapeutics	15.43%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	262.64 million	254.76 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	48.52 million	Optionable
SYRE Spyre Therapeutics	73	60.28 million	50.98 million	Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

VOR, AKBA, SYRE, and MLYS Headlines

Recent News About These Companies

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11 at 5:37 AM | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11 at 5:37 AM | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10 at 4:00 PM | globenewswire.com

Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)

July 10 at 2:38 AM | americanbankingnews.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63

July 8, 2025 | americanbankingnews.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

HC Wainwright Predicts Weaker Earnings for Vor Biopharma

July 4, 2025 | americanbankingnews.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

HC Wainwright Upgrades Vor Biopharma (NYSE:VOR) to "Buy"

July 2, 2025 | americanbankingnews.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30, 2025 | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30, 2025 | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30, 2025 | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

Vor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Which Analyst-Favorite Drone Stock Will Come Out on Top?
By Nathan Reiff | June 25, 2025
View Which Analyst-Favorite Drone Stock Will Come Out on Top?
More Than a Monetary Metal: Silver's Case for Outperformance
By Jeffrey Neal Johnson | June 22, 2025
View More Than a Monetary Metal: Silver's Case for Outperformance
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
Sizzling Insider Buys for Your High-Yield Watchlist
By Thomas Hughes | July 8, 2025
View Sizzling Insider Buys for Your High-Yield Watchlist

VOR, AKBA, SYRE, and MLYS Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$3.93 -0.05 (-1.26%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$3.96 +0.02 (+0.64%)

As of 07/11/2025 07:56 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Mineralys Therapeutics NASDAQ:MLYS

$14.49 -0.15 (-1.02%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$14.49 0.00 (0.00%)

As of 07/11/2025 05:10 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Spyre Therapeutics NASDAQ:SYRE

$15.69 -0.27 (-1.69%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$15.00 -0.69 (-4.40%)

As of 07/11/2025 06:00 PM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Vor Biopharma NYSE:VOR

$2.50 +0.19 (+8.23%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.57 +0.07 (+2.80%)

As of 07/11/2025 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time